MX2015003968A - Angiotensina en el tratamiento de condiciones cerebrales. - Google Patents
Angiotensina en el tratamiento de condiciones cerebrales.Info
- Publication number
- MX2015003968A MX2015003968A MX2015003968A MX2015003968A MX2015003968A MX 2015003968 A MX2015003968 A MX 2015003968A MX 2015003968 A MX2015003968 A MX 2015003968A MX 2015003968 A MX2015003968 A MX 2015003968A MX 2015003968 A MX2015003968 A MX 2015003968A
- Authority
- MX
- Mexico
- Prior art keywords
- angiotensin
- treating brain
- brain conditions
- conditions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/14—Angiotensins: Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Hematology (AREA)
- Zoology (AREA)
Abstract
La presente invención proporciona, entre otras cosas, métodos y composiciones para tratar condiciones cerebrales. En algunas modalidades, los métodos incluyen administrar a un sujeto que sufre de o es susceptible a una condición cerebral un péptido de angiotensina (1-7) por vía de una ruta de administración ya sea intravenosa o subcutánea.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261708793P | 2012-10-02 | 2012-10-02 | |
US201261720299P | 2012-10-30 | 2012-10-30 | |
PCT/US2013/062969 WO2014055591A1 (en) | 2012-10-02 | 2013-10-02 | Angiotensin in treating brain conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015003968A true MX2015003968A (es) | 2016-02-05 |
MX366134B MX366134B (es) | 2019-06-28 |
Family
ID=49919223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015003968A MX366134B (es) | 2012-10-02 | 2013-10-02 | Angiotensina en el tratamiento de condiciones cerebrales. |
Country Status (11)
Country | Link |
---|---|
US (4) | US8633158B1 (es) |
EP (1) | EP2903605B1 (es) |
JP (2) | JP6302916B2 (es) |
KR (1) | KR20150067228A (es) |
CN (1) | CN104837485A (es) |
AU (2) | AU2013327453A1 (es) |
CA (1) | CA2885912A1 (es) |
ES (1) | ES2689781T3 (es) |
MX (1) | MX366134B (es) |
RU (2) | RU2018120387A (es) |
WO (1) | WO2014055591A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8633158B1 (en) | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
JP6254692B2 (ja) * | 2013-07-03 | 2017-12-27 | ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | 認知機能不全を治療するための方法 |
US9333233B2 (en) * | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
WO2016010844A1 (en) * | 2014-07-14 | 2016-01-21 | Tarix Pharmaceuticals Ltd | Methods and compositions for the treatment of stroke |
US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
WO2016014342A2 (en) * | 2014-07-21 | 2016-01-28 | Arizona Board Of Regents For The University Of Arizona | Ang-(1-7) derviative oligopeptides and methods for using and producing the same |
CN106699844B (zh) * | 2015-07-13 | 2020-07-03 | 首都医科大学 | The-RGDVGRPAK十肽,其制备,活性及应用 |
CN106699843B (zh) * | 2015-07-13 | 2020-07-28 | 首都医科大学 | RGDVGRPAK-The十肽,其制备,活性及应用 |
US20180200326A1 (en) * | 2017-01-09 | 2018-07-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) and derivative oligopeptides for the treatment of traumatic brain injury and other cognitive impairments |
CN109553658B (zh) * | 2018-12-13 | 2022-10-04 | 重庆大学 | Ang-(1-7)的氮杂多肽类似物、制备方法及应用 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244946A (en) | 1979-06-11 | 1981-01-13 | The Salk Institute For Biological Studies | Water-soluble peptides affecting gonadal function |
US4305872A (en) | 1979-10-19 | 1981-12-15 | Kenneth Wingrove | Polypeptide derivatives |
US4316891A (en) | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
SU1067796A1 (ru) | 1981-10-30 | 1986-01-15 | Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср | Циклический аналог ангиотензина,обладающий способностью ингибировать прессорное и миотропное действие ангиотензина |
ATE210677T1 (de) | 1993-09-24 | 2001-12-15 | Univ Southern California | Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung |
EP0745091A4 (en) | 1993-09-24 | 1998-05-20 | Univ Southern California | USE OF ANGIOTENSIN II ANALOGS IN TISSUE RECOVERY |
US5955430A (en) | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
US5834432A (en) | 1995-06-06 | 1998-11-10 | The University Of Southern California | Use of angiotensin II Type 2 receptor agonists in tissue repair |
US6031072A (en) | 1996-07-12 | 2000-02-29 | Mcgill University | Compounds and methods for modulating cell adhesion |
US6110895A (en) | 1996-12-16 | 2000-08-29 | University Of Southern California | Method of promoting healing in skin grafts |
US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
US5917151A (en) | 1997-08-29 | 1999-06-29 | Ut Automotive Dearborn, Inc. | Multi-shot molds for manufacturing wire harnesses |
SG92610A1 (en) | 1997-10-24 | 2002-11-19 | Univ Singapore | The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis |
US6248587B1 (en) | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
CA2310852A1 (en) | 1997-11-26 | 1999-06-03 | University Of Southern California | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
AU2591699A (en) | 1998-02-09 | 1999-08-23 | University Of Southern California | Method of promoting erythropoiesis |
US6455500B1 (en) | 1998-03-10 | 2002-09-24 | University Of Southern California | Radiation therapy methods |
US7173011B2 (en) | 2000-11-20 | 2007-02-06 | University Of Southern California | Radiation therapy methods |
JP3728400B2 (ja) | 1998-03-10 | 2005-12-21 | ユニヴァースティ オブ サザーン カリフォルニア | 改良型放射線治療の諸方法 |
WO1999046285A2 (en) | 1998-03-11 | 1999-09-16 | University Of Southern California | Method of promoting production of living tissue equivalents |
EP1067952A1 (en) | 1998-04-09 | 2001-01-17 | University Of Southern California | Methods for treatment and prevention of infections |
EP1073453B1 (en) | 1998-05-11 | 2005-04-13 | University Of Southern California | Use of angiotensin analogs for the manufacture of a medicament for increasing white blood cell survival and mobilizing haematopoietic progenitor cells following chemotherapy |
US6762167B1 (en) | 1998-05-11 | 2004-07-13 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
CA2328871C (en) | 1998-07-13 | 2002-10-01 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
US6916783B2 (en) | 1998-07-13 | 2005-07-12 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
EP1105149A1 (en) | 1998-08-13 | 2001-06-13 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
US6730775B1 (en) | 1999-03-23 | 2004-05-04 | University Of Southern California | Methods for limiting scar and adhesion formation |
ATE335496T1 (de) | 1999-03-23 | 2006-09-15 | Univ Southern California | Angiotensin ii und analoga zur begrenzung von narben und adhäsionbildung |
YU78601A (sh) | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
US7338938B2 (en) | 1999-05-10 | 2008-03-04 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
AU1792901A (en) | 1999-12-16 | 2001-06-25 | University Of Southern California | Methods for treating and preventing diabetic complications |
US6821953B1 (en) | 1999-12-16 | 2004-11-23 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
ATE287724T1 (de) | 1999-12-16 | 2005-02-15 | Univ Southern California | Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes |
AU2001231154A1 (en) | 2000-01-24 | 2001-07-31 | Adherex Technologies Inc. | Peptidomimetic modulators of cell adhesion |
AU2001218024A1 (en) | 2000-06-19 | 2002-01-02 | University Of Southern California | Methods for treating and preventing alopecia |
US6747008B1 (en) | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
AU2002308522A1 (en) | 2001-05-01 | 2002-11-11 | University Of Southern California | Methods for inhibiting tumor cell proliferation |
BRPI0105509B8 (pt) | 2001-11-05 | 2021-05-25 | Univ Minas Gerais | formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga |
CA2467095A1 (en) | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
BRPI0502497A (pt) | 2005-06-28 | 2007-02-06 | Univ Minas Gerais | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
BRPI0602366B1 (pt) | 2006-04-26 | 2017-12-12 | Universidade Federal De Minas Gerais | Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications |
WO2008130217A1 (en) | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
AT506258A1 (de) | 2007-12-18 | 2009-07-15 | Apeiron Biolog Forschungs Und | Behandlung inflammatorischer krankheiten |
EP2077119A1 (de) | 2007-12-21 | 2009-07-08 | Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. | Behandlung von Fibrosen und Lebererkrankungen |
BRPI0800585B8 (pt) * | 2008-02-13 | 2021-05-25 | Univ Minas Gerais | composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) |
US20090227507A1 (en) | 2008-03-10 | 2009-09-10 | University Of Southern California | Angiotensin (1-7) Dosage Forms and Uses Thereof |
AT506632A1 (de) | 2008-04-09 | 2009-10-15 | Apeiron Biolog Forschungs Und | Behandlung von tumorerkrankungen |
ES2393455T3 (es) * | 2008-09-12 | 2012-12-21 | Charité-Universitátsmedizin Berlin (Charité) | Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas |
CL2008003736A1 (es) | 2008-12-15 | 2009-05-29 | Univ Pontificia Catolica Chile | Uso de angiotensina (1-9) para preparar un medicamento, util para prevenir, revertir y/o disminuir el remodelado cardiovascular, pulmonar, renal y/o cerebral. |
RU2011138165A (ru) | 2009-02-17 | 2013-03-27 | Зигнис Байосайенс Гмбх Унд Ко. Кг | Применение g-csf для удлинения периода "терапевтического окна" тромболитического лечения инсульта |
EP2455388A1 (en) * | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
CA2863699A1 (en) | 2012-02-10 | 2013-08-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of peripheral vascular disease |
US8633158B1 (en) | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
US9333233B2 (en) | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
-
2013
- 2013-01-28 US US13/752,202 patent/US8633158B1/en active Active
- 2013-05-17 US US13/897,051 patent/US9511055B2/en active Active
- 2013-10-02 CA CA2885912A patent/CA2885912A1/en not_active Abandoned
- 2013-10-02 AU AU2013327453A patent/AU2013327453A1/en not_active Abandoned
- 2013-10-02 WO PCT/US2013/062969 patent/WO2014055591A1/en active Application Filing
- 2013-10-02 EP EP13844187.8A patent/EP2903605B1/en active Active
- 2013-10-02 ES ES13844187.8T patent/ES2689781T3/es active Active
- 2013-10-02 JP JP2015534823A patent/JP6302916B2/ja active Active
- 2013-10-02 RU RU2018120387A patent/RU2018120387A/ru not_active Application Discontinuation
- 2013-10-02 RU RU2015110114A patent/RU2661109C2/ru not_active IP Right Cessation
- 2013-10-02 MX MX2015003968A patent/MX366134B/es active IP Right Grant
- 2013-10-02 CN CN201380062800.XA patent/CN104837485A/zh active Pending
- 2013-10-02 KR KR1020157011035A patent/KR20150067228A/ko not_active Application Discontinuation
-
2016
- 2016-10-24 US US15/332,813 patent/US20170258766A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/870,233 patent/US20190000809A1/en not_active Abandoned
- 2018-03-05 JP JP2018038469A patent/JP6472914B2/ja active Active
- 2018-07-13 AU AU2018205186A patent/AU2018205186B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170258766A1 (en) | 2017-09-14 |
RU2661109C2 (ru) | 2018-07-11 |
KR20150067228A (ko) | 2015-06-17 |
JP2018090625A (ja) | 2018-06-14 |
AU2018205186B2 (en) | 2020-04-09 |
US8633158B1 (en) | 2014-01-21 |
WO2014055591A1 (en) | 2014-04-10 |
EP2903605A1 (en) | 2015-08-12 |
US20190000809A1 (en) | 2019-01-03 |
CN104837485A (zh) | 2015-08-12 |
US9511055B2 (en) | 2016-12-06 |
ES2689781T3 (es) | 2018-11-15 |
JP2015532291A (ja) | 2015-11-09 |
CA2885912A1 (en) | 2014-04-10 |
EP2903605B1 (en) | 2018-08-15 |
EP2903605A4 (en) | 2016-03-23 |
AU2018205186A1 (en) | 2018-08-02 |
JP6302916B2 (ja) | 2018-03-28 |
RU2018120387A (ru) | 2018-11-15 |
RU2015110114A (ru) | 2016-11-27 |
US20140094497A1 (en) | 2014-04-03 |
MX366134B (es) | 2019-06-28 |
JP6472914B2 (ja) | 2019-02-20 |
AU2013327453A1 (en) | 2015-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018205186B2 (en) | Angiotensin in treating brain conditions | |
AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
MX2013010376A (es) | Formulaciones estables para inyeccion parenteral de farmacos de peptido. | |
PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
IN2015DN01156A (es) | ||
NZ709392A (en) | Synergistic bacterial compositions and methods of production and use thereof | |
MX2019014761A (es) | Manejo de toxicidad para actividad antitumoral de cars. | |
SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
MX350378B (es) | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. | |
WO2014052360A3 (en) | Glycoprotein preparations | |
MX2013004061A (es) | Analogos de ciclosporina. | |
MX367970B (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafinib. | |
MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
MY172699A (en) | Implantable medical devices with increased immune tolerance, and methods for making and implanting | |
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
MX2013004062A (es) | Analogos de ciclosporina. | |
MX2021002513A (es) | Composicion que comprende desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13) para administracion subcutanea. | |
MY191932A (en) | Chitosan-derived compositions | |
MD20140123A2 (ro) | Agenţi terapeutici optimizaţi pentru administrare subcutanată | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
GB201013785D0 (en) | Treatment | |
GB201115977D0 (en) | Neurodevelopmental disorders | |
MX359171B (es) | Tratamiento para diabetes tipo i y tipo ii. | |
GB201114923D0 (en) | Immunogenic proteins and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |